List of Genetic Analysis/Screening Companies in United States - 225

Cells are the basic unit of life. They power everything we do, and unlocking their secrets is the key to advancing our knowledge of every facet of biology, from development to disease. Our single cell, spatial, and in situ tools enable researchers to answer pressing questions about cells and their functional contributions to oncology, immunology, neuroscience, and much more—as evidenced by more than 5,500 publications citing our technology. We are dedicated to building the best products, delivering the best customer experience, and creating the best team to fuel new scientific discovery, no matter how challenging. And we won’t stop until all of the cells’ secrets are revealed.

The 2bPrecise platform integrate genomic data withclinical knowledge and genomic research to identify relevant information for clinical care.

We are a clinical stage diagnostics company committed to developing and commercializing novel products for the treatment and management of all cancers.

We’re leveraging advances in genetics and precision medicine to develop new therapeutics that target shared, underlying biology in rare and common diseases — bringing meaningful medicines from one to many. With expertise in genetics, drug discovery and data sciences, we seek to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics for patients.

ActX, Inc. is a dynamic venture that is focused on making patient genomic information truly useful in everyday medical practice. We are currently seeking a Linux System Administrator/DevOps Specialist to work in a unique, small team environment where innovative new processes assist everyone's productivity. Join our team and help us make personalized medicine a reality rather than a dream!

Aegea Biotechnologies, Inc. is a technology company that is developing a series of reagents, research kits and in-vitro diagnostic (IVD) products for molecular analysis based on novel, patented and proprietary nucleic acid chemistries and methodologies.

Agena Bioscience® empowers research laboratories worldwide to deliver scalable targeted genomic data. Our advanced platforms deliver timely molecular insights in the areas of mutation profiling, liquid biopsy, pharmacogenetics, and more. Agena offers the MassARRAY® System, an open platform that provides researchers with insights through a highly multiplexed solution. Headquartered in San Diego, with offices located around the world, Agena Bioscience fosters a highly collaborative culture for both our customers and employees, encouraging diversity, creativity, and most importantly, innovation.

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/

Alcala Labs was founded by a partnership between a healthcare attorney specializing in the defense of individual and institutional healthcare providers and a physician with one of the largest pain management practices in Southern California. The lab grew out of frustration with existing laboratory providers and the conviction that Alcala Labs could do better. Smaller labs were not scientifically up to the task and, in many cases, were simply dishonest about the services they provided. Larger labs were either unresponsive or subcontracted critical complex lab services to unaccountable third-party labs . Alcala Labs was built to react quickly to the needs of physicians who need to understand drug use and efficacy in their practices. The Alcala difference is accessibility to its physician customers, responsiveness to their needs and inquiries, and customizable lab testing. If a physician has a medical-legal question that arises from testing, he can immediately reach the company's healthcare attorney President. If a physician requires insight into how a particular test affects the course of a patient's care, she can engage in a dialogue directly with the lab's Medical Director. If there are questions about science and the development of new tests, our highly credentialed scientific team can be reached directly. Widely in demand among a variety of specialties, Alcala Labs is of especial importance to drug rehabilitation, pain management, and psychiatry practices. We're able to add assays as illicit "designer" drugs begin to appear, and our new pharmacogenetic department gives physicians the power to anticipate the right drugs and dosages to best treat their patients. Located in San Diego, Alcala is a laboratory of national reach and reputation. It is among the fastest growing labs in the country, dedicated to state-of-the-art science and the highest quality service.

Alida Biosciences is an early-stage, VC backed startup in San Diego focused on developing novel genomic analysis tools. The company’s technology will advance the understanding of RNA biology and provide actionable information for improving human health.

AlphaBiolabs provides DNA testing to members of the public.

Ambry Genetics is a company built by scientists, genetic counselors and physicians, dedicated to leading the clinical genomic diagnostic industry. Ambry boasts the largest genetic sequencing lab in the world; is CAP-accredited, CLIA-licensed and, as part of the Konica Minolta family, has access to the most complete suite of diagnostic technology in the world. Ambry Genetics'​ scope of clients includes some of the world's most respected academic institutions, pharmaceutical companies and leading treatment hospitals. Our experience, technology and dedication to science make us a trusted source for all clinical genetic testing, and an ideal partner for developing precision medicine solutions. Patients are at the core of everything we do, which is why Ambry partners with several non-profit organizations so that we can help both patients and clinicians alike find answers. Hiring Fraud Alert: Ambry/REALM IDx has received reports of employment scams in recent months that seek financial commitments, or requests personal information from job candidates. Unsuspecting job seekers have reported receiving unsolicited contacts by phone, email or text from individual(s) posing to be or represent Ambry/REALM IDx recruiter(s). If you've experienced either of these scenarios, please visit this page to learn more about hiring fraud: https://consumer.ftc.gov/articles/job-scams. Or visit https://realmidx.com/careers/recruitment-fraud-alert/ to learn more about our policy on recruitment fraud. You can confirm the legitimacy of a job posting by viewing our current open roles at https://realmidx.com/careers/.

AMD Biotech, Inc. was founded with a prime focus on the development of nano-magnetic bead technology and its capabilities. Through in-depth research and development, AMD Biotech, Inc. has established the unique technology and production system of nano-magnetic particles for array of products.

We are the curious. Ancestry®, the global leader in family history and consumer genomics, empowers journeys of personal discovery to enrich lives. With our unparalleled collection of more than 60 billion records from 88 countries, over 3 million subscribers and over 25 million people in our growing DNA network, customers can discover their family story and gain a new level of understanding about their lives. Over the past 40 years, we've built trusted relationships with millions of people who have chosen us as the platform for discovering, preserving and sharing the most important information about themselves and their families. Ancestry has over 1,300 employees in locations across the globe. Our headquarters is in Lehi, Utah and our offices are located in San Francisco, California; Lehi, Utah; Dublin, Ireland; Paris, France; London, England; Sydney, Australia; and Grafing, Germany. We are committed to our location flexible work approach, allowing you to work from where you want — in an office or from home or a hybrid of both (subject to location restrictions and roles that are required to be in the office). We will continue to hire and promote beyond the boundaries of our office locations, to enable broadened possibilities for employee diversity. We're passionate about using technology to create simple, useful, and delightful experiences that enrich lives and connect families and have accelerated product innovation to enable everyone to discover, craft and connect around their family story. Ancestry is continually looking for talented, hard-working and curious individuals who are passionate about bringing this mission to life. Sound like you? Join the curious. Visit https://careers.ancestry.com

Generate a Rapid DNA identification profile, anywhere, in less than 2 hours. FBI NDIS approved. Used around the world in public safety, investigations, disaster victim identification, sexual assault, booking, anti human trafficking, border control, counterterrorism, and environmental protection. The ANDE system is revolutionary with respect to its time to actionable result, ruggedization, complete end-to-end functionality, cost-effectiveness, and ease of use (so easy that a technical operator is not required).

At Ansa Biotechnologies, we’re developing a way to synthesize DNA that will accelerate innovation in medicine, agriculture, and industrial biotechnology. Our fast, clean, and accurate enzymatic DNA synthesis process can produce gene-length molecules directly, overcoming bottlenecks of traditional DNA synthesis methods. We envision a future where our technology empowers scientists to develop solutions for the world's biggest problems in health and sustainability. Note that Ansa does not conduct any employment discussions via LinkedIn. All official Ansa career openings are exclusively listed on our website careers page.

Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants. Apriori was founded in 2020 in Flagship Labs, a unit of Flagship Pioneering.

Aranscia unlocks the power of precision medicine by serving the needs of clinical professionals directly within the care workflow.

Arima-HiC is a proximity ligation method that captures the three-dimensional organizational structure of chromatin, where genomic sequences that are distal to each other in linear distance can be closer to each other in the 3D space. The high-resolution, genome-wide map of interacting genetic loci that is generated from Hi-C data can then be used across multiple genomic applications including identification of promoter-enhancer interactions for gene regulation studies and scaffolding contigs for genome assemblies to define chromosomes de novo.

ARQGenetics offers custom-designed gene panels to provide accurate real-time gene expression data.

ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development. A nonprofit enterprise of the University of Utah, ARUP offers an extensive test menu of highly complex and unique medical tests. With more than 3,000 employees, ARUP offers in excess of 3,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays. ARUP is an Equal Opportunity Employer M/F/D/V and supports a drug-free environment. Scammers have been posing as ARUP recruiters to target jobseekers using fraudulent email addresses and social media accounts. ARUP recruiters will only contact you with legitimate offers by calling from 800-522-2787 or 801-583-2787 or emailing from an address ending in @aruplab.com. Read our full fraud statement on aruplab.com/careers

Focusing on developing the best nucleic acid amplification and detection technologies for clinical molecular diagnostics - COVID-19 (FDA EUA Approved), Non Invasive Prenatal Test, HPV Detection, STI, NGS Cancer Panel (Lung, Breast, Colorectal), and many more.

AutoGenomics is a biotechnology company that offers an automated microarray based multiplexing molecular diagnostic platform to assess disease signatures with novel genetic biomarkers in the areas of women’s health, cancer and personalized medicine.

Baylor Genetics offers a full spectrum of cost-effective, genetics testing and provides clinically relevant solutions. They offer whole exome sequencing, prenatal diagnostics, cytogenetics, molecular diagnostics, oncology, chromosomal microarray analysis, and over 30 enzyme assays. Along with these tests come interpretation services.

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ mice), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with more than 70% of the top 50 pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world.

Biofidelity is a rapidly growing commercial-stage genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world. We have launched our first product, ASPYRE-Lung, in the US and we have an extensive pipeline of novel products. Biofidelity has developed a novel molecular biology technology which enables genomic analysis for cancer diagnosis to be carried out locally, quickly and far more cost-effectively.

Biomeme's platform transforms your smartphone into a mobile lab for advanced DNA diagnostics and real-time disease surveillance. The system includes a docking station for real-time PCR, a mobile app to control the system and analyze results, and targeted test kits for preparing samples and identifying pathogens or diseases by their specific DNA or RNA signatures. The cutting edge platform performs to the gold standard used by the world's most advanced central labs but requires no lab equipment or special experience to use. The low-cost, user-friendly system enables mobile testing at the point-of-need for health care (mobile clinics, disease tracking, home use), agriculture (plant disease tracking, food safety), vector surveillance (Malaria, West Nile mosquitos), veterinary medicine, environmental monitoring (soil and water safety), and even education and citizen science.

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research. Bionano also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through our Bionano Laboratories business, wey also offer OGM-based diagnostic testing services.

Bionexus offers a comprehensive line of biomedical products and services for the scientific community.

BioPet Laboratories is a biotechnology company specializing in animal genomics. BioPet offers multiple product and services: PooPrints®, the DNA Solution for Dog Waste; BioPet Life Plan™, an interactive canine health and wellness management tool with Breed and Allergy Testing; DNA Proof of Parentage, canine parentage testing certification; Travel Dog™, an elite club for dogs and their owners; and the DNA World Pet Registry®, a state of the art database to store canine genetic information. As the parent company of the PooPrints® program BioPet works with more than 7,000 multifamily properties worldwide. With more than 800,000 individual canines in their database, BioPet is becoming an industry standard for canine genetics. BioPet was the first to offer a ground breaking price point reductions and one of the fastest processing times in the canine paternity industry. Historically excelling in canine DNA offerings such as breed analysis, parentage verification, and DNA matching of fecal samples, BioPet continues to expand its offerings in genetics and forensics. *BioPet Laboratories is accredited to the ISO/IEC 17025:2017 standard*

We provide services in genomics, statistics, and information technology. Our services include Bayesian analysis, bioinformatics, biomarker development, biostatistics, data management, data pipelines, data science, epigenomics, genetics, genome-wide association, imputation, microarray analysis, multiomics, next-generation sequencing analysis, pharmacogenomics, polygenic risk scores, predictive modeling, project management, proteomics, reproducibility, software development, statistical computing, statistical genetics, and statistical programming. We also developed the Smokescreen® Genotyping Array, advancing research into addiction and treatment approaches. Our highly-skilled transdisciplinary team of experts, carefully assembled from leading research universities and industry, has been solving our clients' research challenges for almost two decades. Extensive experience with a wide range of cutting-edge methods and technologies means we can help ensure your project's success, and provide high-quality deliverables on time and within budget. Whether you have a critical issue, need help with every aspect of a new project—including coordinating complex projects—or only one part of an ongoing project, we can work with you to develop the optimal solution to meet your goals and objectives. Our team can be an integral part of the collaboration, and provide full-service support for all the stages of your research journey. We follow all U.S. Department of Health & Human Services standards for the security of electronic protected health information (HIPAA-compliant). We believe in reproducible, reusable, transparent, and extensible research, and do everything we can to put those values into practice. We are prepared to use our internal computing environment, cloud-computing environments, or client-provided environments, if preferred.

For more than four decades, BioReference has built a legacy based on scientific excellence, innovation and world-class service in laboratory testing solutions. Amidst a tidal wave of change in healthcare in recent years, BioReference has evolved, adding significant services and solutions aimed at addressing the needs of today’s customers. Laboratory testing remains the cornerstone to the services we provide. As we challenge the limits of specialty diagnostics, we are making strategic investments to continue drive innovation and cultivate a unique customer experience, as well as expanding our reach to match the dynamic needs of an ever-changing healthcare system. BioReference offers scientific expertise and laboratory innovation in oncology, urology, and women’s health. Our organization provides credible and tailored solutions for a wide spectrum of customers and patients, including medical practices small and large, hospitals and health systems, correctional institutions, government agencies, educational systems, sport leagues, travel and leisure industries, and retail markets. In addition to an extensive test menu with 99% of tests performed in-house, BioReference’s differentiated offerings include large-scale health screening programs, on-demand mobile phlebotomy, and transformative business solutions that optimize laboratory testing and management. BioReference is part of OPKO Health, Inc., a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets. Headquartered in Elmwood Park, New Jersey, BioReference operates 10 laboratory facilities around the country, is in-network with the largest health plans in the United States, and serves over 19 million patients annually.

BioSkryb is a venture-backed startup bringing new solutions for cellular heterogeneity, in both the research and clinical space studies, using a proprietary genome amplification system.

BioSpyder Technologies has developed a novel product for targeted sequencing called TempO-Seq™, a gene expression profiling tool designed to monitor hundreds to thousands of genes at once in high throughput. TempO-Seq can analyze expression in samples with thousands of cells or from single cells without pre-amplification, maximizing utilization of precious or limited samples. Sample barcoding, together with sequencing short fragments of each gene, enables pooling up to 6,144 samples in one sequencing run. Assay content is flexible and customizable delivering unprecedented accuracy and sensitivity.with simplified data analysis that eliminates the need for bioinformatics. TempO-Seq assays deliver an easy to use solution for customers doing expression profiling for any species.

Biotia is a health tech company launched from Jacobs Technion-Cornell Institute at Cornell Tech in association with Weill Cornell Medicine, located in New York, NY, that leverages DNA sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Biotia is developing a next-generation sequencing-based test for COVID-19 that characterizes genetic variance across the whole viral genome.

Blue Heron has been collaborating with some of the most brilliant minds in the industry to create millions of complex genes using our proprietary GeneMaker® multi-technology platform. We are the first gene synthesis company founded and solely operated in the USA. Our only location in Bothell, Washington subjects us to strict U.S. standards for Intellectual Property (IP) Policy and ensures every contract for each customer is confidential. Because of our simple flat rate pricing, we deliver what no other company can provide — the assurance your project will proceed as quoted. Utilizing high grade reagents and proprietary technology we produce DNA of the utmost quality. Our aptitude for projects involving unusually long or difficult sequences allows clients to eliminate errors, risk, and costs that are simply no longer a necessary part of the research process. Blue Heron Provides: - Dedicated Customer Service - Simple Pricing - Easy Ordering - Strict Client Confidentiality - Guaranteed Turnaround Time - Sequence Design - Synthesis of Genes up to 50KB - Complex Genes (hairpins, repeats) - 100+ IP free Expression Vectors - Free Codon Optimization - Free Archiving Publications Citing Blue Heron Biotech Gene Synthesis: http://www.blueheronbio.com/assets/documents/citations/BlueHeronBiotechCitations.pdf

Blueprint Genetics is a genetic diagnostics company focused on inherited diseases. We provide world-class genetic diagnostics and clinical interpretation for hereditary diseases. We are passionate about changing peoples’ lives through development of groundbreaking solutions that take genetic diagnostics from niche to mainstream. Our global team of innovative and motivated people are working at the forefront of genetic knowledge, AI and other areas of life science. Our team consists of more than 20 nationalities working as geneticists, data analysts, laboratory technicians, client service specialists, genetic services consultants, software developers and marketing specialists. Today, we work with customers in over 70 countries and push to make genetic knowledge easier to access for the medical community. Our comprehensive and cost-effective genetic tests support healthcare professionals around the world in providing the best care for patients and families with rare inherited diseases.

Bruker Spatial Genomics, Inc, (formerly Acuity Spatial Genomics, Inc.) provides a groundbreaking platform for simultaneous, genome-wide visualization of the 3D genome in single cells and opens new frontiers in spatial multiomic analyses for discovery. Based on patented technologies developed at Harvard University, the company’s jebFISH™ technology empowers researchers to directly visualize genome organization and 3D chromatin architecture of individual cells, directly in situ. The company’s transformative PaintScape™ platform, powered by jebFISH technology, breaks through challenges of multiplexed, direct imaging of the genome in nuclei and makes it possible to gain critical insight into cell programming and transcription regulatory programs that drive cell type, state, and function. Directly seeing changes and disruptions of genome organization will elucidate mechanisms of disease and its progression especially in disease systems like cancer. Bruker Spatial Genomics, Inc. is part of Bruker’s strategic investment in spatial biology and its initiative to develop and expand emerging spatial analyses technologies. The PaintScape platform joins the portfolio of high-performance Bruker Spatial Biology platforms that empower researchers to delve deeper and advance discovery in life science and translational research.

Cantata Bio is enabling researchers and clinicians to solve tomorrow’s most challenging scientific problems through novel, multiomic approaches that unlock access to genomic and metagenomic information at unprecedented levels. Combining propriety technologies with platform solutions, services, and cutting-edge bioinformatics and software, our unique approaches are solving complex problems, including chromatin topology analysis, small and large structural variant detection, de novo chromosome assembly, haplotype phasing, metagenomics, and microbiome analysis. Our customers are positively impacting the fields of epigenetics, developmental biology, cancer research, evolutionary biology, infectious disease, and more. Cantata Bio is based in Scotts Valley, California and Cambridge, Massachusetts. For more information on Cantata Bio, its technology, and offerings, visit www.cantatabio.com.

Celemics is a Next Generation Sequencing (NGS) full solution provider based on target enrichment technology. We confidently offer custom target enrichment panels and high-quality pre-set panels, covering fields such as Inherited Diseases, Oncology, Immunology, and Pathogen Diagnostics. With 13 years of experience, we will provide the best solution for your Targeted Sequencing. [Products/Services] OncoRisk (Hereditary Cancer) | CancerScreen (Somatic Cancer) | Custom Target Enrichment Panel | Whole Exome Sequencing | Clinical Exome Sequencing | BRCA 1/2 | PharmacoScreen | Comprehensive Respiratory Virus | Agrigenomics

Cellecta provides HT loss-of-function genetic screening services for the discovery and functional characterization of novel therapeutic targets. We offer pooled lentiviral shRNA and CRISPR libraries, pooled library screening and analysis by NGS, targeted RNA-Seq for biomarker discovery, lentiviral reagents, and stable cDNA, shRNA, and CRISPR constructs and isogenic cell lines.

Cincinnati Children's, a nonprofit academic medical center established in 1883, offers services from well-child care to treatment for the most rare and complex conditions. It is the Department of Pediatrics at the University of Cincinnati College of Medicine and trains more than 600 residents and clinical fellows each year. Cincinnati Children's is a force in pediatric research and offers some of the best research-based education and training programs in the nation. We are proud to be an Equal Opportunity Employer that values and treasures Diversity, Equity, and Inclusion. We are committed to creating an environment of dignity and respect for all our employees, patients, and families (EEO/AA).

We are an early-stage biotech startup based in Santa Cruz. We are a small, motivated, multi-disciplinary team innovating in NGS sequencing technologies and DNA assay design for applications in molecular diagnostics with focus on liquid biopsies, FFPE and ancient DNA Interested in beta testing our single-stranded approach to NGS library prep? Get in touch! www.claretbio.com/contact We are always looking to build our team with seasoned scientists who want to be on the ground-level of ground-breaking technology.

Invitae, now part of Labcorp, is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We're working to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of our mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Within each of us lies information coded in our DNA that can transform our health. Unlocking that potential requires highly specialized, multidisciplinary collaboration. Our world-class genetics experts drive the development of a highly complex system of tools and processes, including robotics, artificial intelligence, machine learning, and software engineering. All of this comes together to provide patients with accurate, reliable results that can help guide decisions across the healthcare journey and potentially change lives today and for the next generation. Our teammates are grounded in a universal sense of urgency and ownership. We believe in the team above the individual and celebrate freedom with accountability. Employees are encouraged to speak up, try new things and make decisions that push us forward. We provide all Invitaens with opportunities to grow and advance, supported by flexible work hours, unlimited paid time off, the ability to work anywhere for many roles and the satisfaction of doing meaningful work. At Invitae, we're putting patients' genetic insights where they belong—at the center of healthcare. And we're doing it together, with you. Join us.

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applications to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy - from food-borne pathogens to infectious diseases, including SARS CoV-2. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens.

Codetta Bio is a company developing an integrated platform for highly multiplexed, quantitative, simultaneous multi-omic analyses of nucleic acid and protein assays. They are focused on precision medicine and accelerating clinical success through their advanced multi-omic biomarker measurement tools.

Genetic testing, direct to consumerCOVID-19: EUA (05/2020) for their LAMP (Loop-mediated amplification) and uses three SARS-CoV-2-specific primer sets targeting the SARS-CoV-2 nucleocapsid gene (N), the envelope gene (E), and the ORF1a region.

The science of genetics. The business of discovery. Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics. Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth. Colossal is accepting humanity's duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies.

Working on turning stem cells into human eggs

MAVEvidence is the premier functional evidence resource for the clinical genetics community. MAVEvidence delivers increased productivity and time savings through comprehensive curation, rigorous analysis, and clear presentation of functional evidence derived from high-throughput studies of genetic variants. The MAVEvidence platform contains more than 187,000 pieces of evidence across 125,000 genetic variants, and is continually updated with data from the latest functional studies.

Coriell Life Sciences (CLS), an international leader in precision medicine, delivers DNA testing benefits that empower the most precise medical care, improve population health, and reduce healthcare costs. We work with retirement systems, pension funds, health plans, employers, public and private organizations, pharmacy benefit managers (PBMs), benefits brokers, and laboratories around the globe to eliminate needless risks, costs, and waste associated with trial-and-error prescribing. https://www.youtube.com/c/CoriellLifeSciences

Cramer Fish Sciences (CFS) is an employee owned fisheries research consulting firm with offices in Oregon, California, Idaho and Washington. Established in 1987, CFS provides a fantastic work environment that fosters growth and learning in a casual yet productive atmosphere. Our mission is to rigorously apply the scientific method to afford our clients innovative, scientifically robust solutions to address a variety of fisheries and environmental challenges. The CFS team achieves these high standards through effective and unbiased data collection, insightful analysis and interpretation, and clear communications. Visit our website at www.fishsciences.net.

Creative Genomics(CG) specializes in providing the services of DNA sequencing, genotyping and library construction in the global market. Our state-of-the-art sequencers including ABI3730xl, Roche 454 GS-FLX System and Illumina Solexa 1G Genome Analyzer make our customer-oriented DNA sequencing services to stand out with efficiency, reliability and flexibility. Coupled with a variety of high definition genotyping platforms such as Illumina BeadStation 500, Beadxpress and Sequenom, a full range of services from whole genome scans to targeted SNP genotyping can be provided with a high turnover rate. In addition, theyhave professional team members with extensive experience in library construction. Above all these, an in-house Laboratory Information Management System (LIMS) as well as manual basecalling by senior bioinfomaticians ensuresservices with the highest quality.

CureMatch is a leader in AI-based precision medicine, digital decision support solutions that support cancer treatment. Created to empower oncologists with world-class research and sophisticated AI algorithms, the CureMatch Decision Support System assists the doctor with understanding therapeutic options that are personalized to the unique molecular profile of the individual patient's tumor.

Developing simple to use technology to understand complex cellular biology. We are a team of scientists passionate about genomic technologies and how innovative technologies fuel new waves of scientific discoveries and clinical applications. Our group consists of reputable inventors in both academia and industry, as well as seasoned biotech entrepreneurs and executives with a strong track record in bringing genomic technologies from concept to commercialization.

We are a well-funded stealth biotech company backed by some of the most experienced operators and investors in the biotech industry. Our co-founders are highly experienced researchers, clinicians, and entrepreneurs, on a mission to improve precision medicine with cutting-edge genomic technology.

We apply modern methods in agricultural biochemistry and genetics to dramatically improve cannabis varieties. These improvements ensure an unmatched experience for the cultivator and consumer alike.

Founded in 1987, DiagnosTechs™ is a pioneer and leader in saliva-based testing. Our commitment to assisting healthcare professionals in restoring patients'​ health and wellness is unsurpassed with over 1.2 million specimens tested per year. Saliva testing is a powerful tool for evaluating stress, hormone-related disease and health conditions, especially over time. DiagnosTechs continually improves and refines its laboratory testing standards, using cutting-edge technology and methods. Many healthcare providers and their patients have chosen DiagnosTechs as their partner in wellness.

DLS is proud to be Hawaii's largest locally-owned clinical testing laboratory with a team of 800+ dedicated professionals. Our Microbiology Lab is the only clinical laboratory in Hawai'i with the WASPLab, a highly advanced specimen processor. Our Core Lab features a chemistry automation line that is the largest of its kind in the state. It also utilizes mobile robots that efficiently deliver samples between processing stations. We know that when it comes to the wide variety of lab tests we perform, quick, accurate results and analyses improve health and save lives. At DLS, we are committed to excellence in laboratory science and stand by our guiding values, I.C.A.R.E.: I - Innovation C - Care A - Aloha R - Respect E - Excellence We work closely and collaboratively with physicians, medical groups, hospitals and clinics. Our employees are what makes DLS a successful company and we strive to provide an environment of growth and professional development for our versatile and high-performing workforce. Beyond lab results, we build relationships and create collaborative partnerships with the communities we serve. No matter what your position is at DLS—medical technologist, medical laboratory technician, technical laboratory assistant, phlebotomist, systems engineer or patient account representative—your role will impact patient health. When it comes to living in Hawai‘i, we at DLS are committed to making our newest members feel at home with guidance and support. We believe in a healthy work-life balance, and we want our team members to take full advantage of our islands' natural beauty and great year-round weather.

We are the first gut microbiome, genetics-based virtual care platform for people struggling with polychronic mental & physical illness associated with weight and gut. We use AI to harness clinical, genetic, gut microbiome, food and behavioral signals to target the root cause of illness. We deliver tailored whole-person care, including remote monitoring, food-as-medicine, pharma reduction, behavioral coaching support, and care coordination. We use AI to harness food information, clinical, genetic, gut microbiome, and behavioral signals, to deliver tailored holistic care, including food as medicine, behavioral coaching support, remote monitoring, and care coordination, to target the root cause of illness. Our customers love us because we acknowledge their unique physiology, lifestyle, food habits and deliver data-driven personalized care supported by specialist coaches that puts the customer in charge.

DNA COMPASS is implementing ‘last mile' bioinformatic solutions which bridge the gap between centers of genomic discovery and community health practices. Bringing to market data analytics and collaboration solutions which support healthcare professionals by extending the reach of data-driven medicine into community practices. WHY: At DNA Compass, we believe linked health data must work harder, faster, and for more patients. It must empower clinicians NOW to accelerate accurate diagnoses, increase treatment success, and deliver better outcomes. BREAST CANCER DEMO http://dnabreast.com

DNA Diagnostics Center is a biotechnology company that specializes in paternity DNA testing and forensic DNA analysis.

DNA Diagnostics Center is a biotechnology company that specializes in paternity DNA testing and forensic DNA analysis.

DNA Link Sequencing Lab is a business unit with DNA Link, Inc, which is dedicated to providing DNA sequencing services to researchers worldwide. Founded in 2000, it has extensive experience in all genomics tools, and our fleet of sequencers include PacBio Sequel, RSII, HiSeq and NextSeq as well as Affymetrix array platforms.

Develop artificial intelligence that is utilized to aid and augment certified genetic counselors and pharmacists, during pre-test, post-test and support services.

Dovetail Genomics is reimagining the life sciences by unlocking access to genomic structure at an unparalleled level. Through Dovetail Genomics' proprietary proximity ligation technologies, the 3-D architecture of the genome is captured alongside primary sequence information using standard next-generation sequencing (NGS) approaches. Researchers are using Dovetail Genomics' unique methods to solve complex problems including chromatin topology analysis, small and large structural variant detection, de novo chromosome assembly, haplotype phasing and microbiome analysis in the fields of epigenetics, developmental biology, cancer research, evolutionary biology and more. Through our services and assay kit offerings, Dovetail Genomics is ready to partner with you to elevate your genome research to a new level. Researchers are using Dovetail Genomics' unique methods to solve complex problems including chromatin topology analysis, small and large structural variant detection, de novo chromosome assembly, and haplotype phasing in the fields of epigenetics, developmental biology, cancer research, evolutionary biology and more. Through our services and assay kit offerings, Dovetail Genomics is ready to partner with you to elevate your genome research to a new level.

DxTerity is bringing the power of precision medicine to autoimmune disease. We are pioneering the use of RNA-based immune system profiling to better understand the root causes of immune mediated conditions. Our goal is to provide more personalized care for autoimmune sufferers and empower patients with more detailed information about their condition so they can better navigate their complex health journey.

EdgeBio has a team of experienced research professionals that are knowledgeable in next generation sequencing technologies and applications. From library preparation through data analysis, EdgeBio representatives are there to discuss your project on a custom basis to ensure that you receive the results you need for your research. Follow us on Twitter at: https://twitter.com/EdgeBio

We are now at the dawn of the synthetic biology revolution, which will spawn new applications, markets, and business models, improving human lives in countless ways. This revolution will be driven by new technologies that enable DNA writing at speed and scale. To catalyze this revolution, Elegen is creating a suite of ground-breaking technologies to achieve DNA writing with unparalleled speed, cost, and quality. Elegen is unlocking the power to reprogram biology and create biologic solutions in order to solve some of humanity's greatest challenges. Founded and led by Dr. Matthew Hill and located in San Carlos, CA, Elegen is a stealth-mode company that is well capitalized by top life science investors, including Andreessen Horowitz, 8VC, and KdT. The company is advised and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger, inventor of the Nanoflex™ valve and former CSO of Fluidigm. Dr. Hill has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success.

Element Biosciences is a multi-disciplinary startup focused on developinggenetic analysis tools for the research and diagnostic markets.

Emendo Biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy. We leverage our expertise in protein engineering to bring innovative and disruptive protein tools to resolve the bottleneck of the field.

Empire Genomics is a leading biotechnology company focused on the development of advanced molecular diagnostics and genomic products. Our mission is to accelerate precision medicine by providing tools that empower researchers, clinicians, and pharmaceutical companies to better understand, diagnose, and treat complex diseases, particularly in oncology. We offer an extensive portfolio of FISH (Fluorescence In Situ Hybridization) probes, ancillary reagents, and custom assay development services. These products are essential for detecting genetic abnormalities, such as gene amplifications, deletions, and rearrangements, critical for diagnosing and monitoring various cancers and genetic disorders. Committed to quality and innovation, our products are rigorously tested to meet the highest industry standards, ensuring reliable results. Selling products globally through a network of distributors, Empire Genomics continues to advance personalized medicine, enabling healthcare providers worldwide to deliver more targeted and effective treatments to patients.

Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.

Erisyon is transforming the field of proteomics with the world's first single molecule protein sequencer. With unprecedented sensitivity and scalability for proteomics, Erisyon enables new applications across the Life Sciences Erisyon has emerged from the University of Texas at Austin to commercialize the world's first single molecule protein sequencer. Inheriting work developed over the course of the past decade at UT's Center for Systems and Synthetic Biology, Erisyon was founded by a group of technologists and entrepreneurs with the ambition to usher in new discoveries that make the world healthier, safer, and more abundant.

Exceltox is a CAP-accredited, CLIA-certified laboratory offering advanced clinical, pharmacogenomic,and toxicology testing.

Express Gene Molecular Diagnostics Laboratory is a CLIA CLIA-certified laboratory located in Miami, Florida. Our focus is genetic testing and we offer several important genetic tests, including pharmacogenomics tests. Pharmacogenetic (PGx) testing is a type of genetic test that assesses a patient's risk of an adverse response or likelihood to respond to a given drug. This gives healthcare providers insight into what medications to use for a given condition. The PGx test allows physicians to make informed, science-based drug selections and appropriately adjust the dosing.

Fauna Bio is inspired by the untapped potential of non-model organism biology. We leverage insights from extraordinary mammalian phenotypes to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans.

For patients whose cancer has returned, First Ascent Biomedical provides new ways to fight by combining functional drug testing, genomics, and artificial intelligence to design an individualized treatment plan in a week for each patient. Our technology rapidly grows tumor bulk, more importantly chemo-resistant cells enabling the testing 100s of FDA-approved drugs to measure the cellular response of both cell populations. This is the key dataset for the AI engine, supported by genomics data to identify every cancer weakness and identify which drugs work.

Single-cell analysis company focused on the high-throughput identification and characterization of neoantigen-specific T-cell receptors.

Floragenex is an biotechnology company that provides innovative solutions for genomic analysis in human, plant and animal systems. With multiple offices located on the US Pacific coast, our technologies allow investigation of genomes at unprecedented levels for academic, governmental and commercial researchers worldwide.

Fore Genomics, a clinically-focused genetics company, has launched FORESITE 360, a leading-edge product offering clinical-grade, in-depth sequencing for the littlest patients. Focusing on newborns and children, a simple cheek swab sample provides doctors and parents with valuable genetic insight into a child's potential for future diseases based on their DNA. Backed by the reliability of CLIA-certified and CAP-approved labs, FORESITE 360 is designed to offer a complete genetic profile of your child, unlocking a lifetime of health insights. FORESITE 360 incorporates ongoing re-analysis of DNA, allowing doctors to take practical steps toward managing any detected medical conditions. Without adding a single item to their to-do list, clinicians can now add value for their patients with leading-edge sequencing, high-quality genetic counseling, and annually updated analysis.

Form empowers scientists to harness the data, computing power and collaboration that drive how today's breakthroughs are made.

Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us. Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike. - Our Products & Services - Fulgent Genetics https://www.fulgentgenetics.com/ Fulgent Oncology https://fulgentoncology.com/ Fulgent BioPharma https://biopharma.fulgent.com/ Picture Genetics https://picturegenetics.com/ HelioLiver https://www.helioliver.com/ Fulgent is a CLIA-certified and CAP-accredited laboratory. _____________ NASDAQ: FLGT

Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond traditional gene sequencing to measuring gene function, Function Oncology aims to identify optimal therapeutic opportunities for patients and advance the next generation of targeted cancer therapies.

Geisinger Medical Laboratories, a medical reference laboratory in Pennslyvania (PA). Dedicated to caring, laboratory excellence, patient safety, quality assurance, and service excellence.

Gencove creates high-volume, cost-sensitive sequencing software-as-a-service to help academic, agriculture, biotech, diagnostic, and pharmaceutical companies get all the genomic information they need to make life-saving discoveries.

At GeneDx, we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test.

Genemarkers is a Kalamazoo, Michigan-based contract services laboratory specializing in genomics research and molecular testing services, with a primary focus on consumer products, dermatology, skin-related research and therapeutics.. Founded in 2008 by former professor and neuroscientist Dr. Anna Langerveld, Genemarkers has proven its expertise through collaborations with cosmetic, pharmaceutical, and academic research institutions over the years. Taking pride in providing actionable, high quality data and customer service, Genemarkers' CLIA-certified and CAP-accredited laboratory has the ability to support a wide range of projects throughout discovery and development including advanced cellular models/exposures (e.g., dermal/transdermal, hepatic/extrahepatic, neuronal and bronchial/inhalation) and next generation bioinformatics and computational modeling.

Our mission is to enable a world where everyone's health is informed by genetics. As a leading telegenetics care delivery company, we make genetics care accessible and actionable for patients throughout the U.S. and Canada through seven-day a week access to genetic services. We partner with health systems, genetic testing laboratories and biopharmaceutical companies. We accelerate, grow and provide service to their patients by launching genetics programs from the ground up, improving the scale and efficiency of existing genomic medicine programs, and providing genetic expertise and services to support clinical trials and sponsored genetic testing programs. With the largest national network of telehealth genetic counselors – averaging 10 years clinical experience – We have delivered more than 200,000 genetic counseling encounters, scaling to more than 8,500 patients per month and helping health systems expand network reach to more patients by delivering genetic care to patients anywhere, seven days a week. We are a covered benefit for 130 million people in the U.S. Through our nationwide virtual care delivery model, we provide genetics care to patients when and where it is most convenient, reducing patient wait times from as much as 18 months to one week. We have an extensive team of clinicians, including medical geneticists, genetic counselors, physicians and pharmacists. Our clinical specialties include oncology, reproductive health, cardiology, pediatrics, rare disease and proactive health.

GENESEARCH, INC is a biotechnology company that specializes in embryonic manipulation techniques for biomedical research purposes.

State-of-the-art diagnostic laboratory providing comprehensive pathology, DNA Sequencing, pharmacogenetic and toxicology testing solutions.

GENETWORx Laboratories was formed with the central focus of impacting the lives of our people by empowering their physicians with information. Now, GENETWORx is dedicating our focus to fighting back against COVID-19. GENETWORx' COVID-19 test is the gold standard due to being 10% accurate, with 10% sensitivity and specificity. GENETWORx's COVID-19 test detects infection in the earliest stage, with a long turnaround time. Once a sample has been received in our laboratory, the prescribing physician will have the result via GENETWORx's portal within 10 business days. GENETWORx provides ongoing COVID-19 testing so that states, employers and organizations can continue or again open their operations with a safe and healthy workforce. We are completing thousands upon thousands of tests a day, and are growing to ensure that everyone in the USA can be tested and return to work. GENETWORx has met the Federal and State licensure requirements to operate in all 50 states. • CAP Number: 8732425 • CLIA Number: 49D2060159 Learn more about COVID-19 Testing: https://www.genetworx.com/faqs Our core values: • Personalized patient-centric care • Translating science into actionable intelligence • Supporting doctors and pharmacists in their delivery of top-quality Personalized Medicine • Enabling cost-effective health care • Preserving patient privacy

Geneyx offers best-in-class practices harnessing #geneticdata available to guide digital insights for rare and #germline disorders and diseases. We aim to enrich disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and #pharmaceutical organizations.

Enabling users to establish #ownership & #control over their Biosamples & derived datasets as Non-fungible Tokens. We call them #BioNFTs 🧬.

Genomenon is a leading genomic intelligence company dedicated to improving the quality of patients’ lives by uncovering the genomic drivers of genetic disease and cancer. Blending the power of AI with genomic expertise, Genomenon simplifies complex genetic data into actionable insights for patient diagnosis and precision medicine development. The company’s solutions include software, data, and services. Genomenon offers advanced genomic software solutions designed to streamline and enhance genetic research and clinical decision-making. Our flagship product, the Mastermind® Genomic Intelligence Platform, provides comprehensive genomic data integration and analysis, offering researchers and clinicians a powerful tool to interpret genetic variants and their clinical relevance. Complementing this is the Clinical Knowledgebase (CKB), which focuses specifically on the landscape of somatic mutations, offering curated, actionable insights to support oncology research and personalized cancer treatment. Together, these platforms aim to accelerate discoveries and improve patient outcomes through sophisticated data analysis and knowledge integration.

Today only 1 out if 4 cancer drugs prolongs life because we treat all the patients the same way. Genomic Expression's OneRNA™ test can save lives and make healthcare delivery more effective by sequencing RNA and linking RNA's to approved therapies and clinical trials.

GenoPalate, Inc. is a science-based nutritional genomics company that is paving the way in the personalized nutrition space by offering revolutionary at-home DNA tests, one-on-one online nutrition programs led by registered dietitians, and personalized supplements. GenoPalate empowers people to reach optimal health through personalized nutrition.

GenoSensor Corporation is a genomic technology company, aiming to improve human healthcare by developing and marketing products and services for genomic research, drug discovery, predisposition gene screening, therapeutic assessment and other bioscience applications. GenoSensor's focus is to provide products and services to customers who conduct genomic research and/or are in needs of genomic solutions in all life sciences. The company also develops assays for specific applications. By means of integrating high-throughput laboratory and microarray fabrication facilities, GenoSensor has become a nationwide leading company in bioassay services and development. Currently, company's genetic products and services are helping laboratories worldwide for their sample processing, nucleic acid preparation, genetic profiling and gene screening. Full services including sample-in and data-out genomic experimentations are provided for the applications of gene expression profiling, genotyping, sequencing and other genomic research. The production pipelines are robust and highly reproducible. The service is reliable, cost-effective, and fast turnaround. Meeting the needs of individual customers is company's key goal.

At Genospace, our mission is to deliver the platform that makes biomedical data useful and usable by everyone. Genospace has built a comprehensive platform for precision medicine to enable interpretation, analysis, reporting and collaboration on high-dimensional genomic and other biomedical data. With specific applications supporting research, development, pathology and clinical care, many of the most advanced precision medicine organizations are powered by Genospace. Please visit www.genospace.com for more information.

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 200,000 customers from over 100+ countries and regions worldwide have used GenScript's premier, convenient, and reliable products and services. GenScript has over 6,900 employees globally, with about 10% R&D personnel. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics, including more than 300 patents and about 900 patent applications. As of December 31, 2023, GenScript's products and services have been cited by 87,745 scientific papers worldwide. GenScript is committed to striving toward its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.

G3 leverages molecular profiles of human health and disease to develop life changing diagnostics and therapeutics.

Gnome Sciences is a U.S.-based, CLIA-certified CRO that specializes in complex histopathology and molecular biology studies. We take pride in our unique capability to undertake challenging projects – the types of studies that larger companies often shy away from and that smaller organizations cannot handle. Our expertise ranges from multiplex IHC/ISH to gene expression analysis, but the thing that really sets Gnome apart is that we love the science and care about your project as much as you do

Meet your business challenges head on with cloud computing services from Google, including data management, hybrid & multi-cloud, and AI & ML.

Process, analyze, and annotate genomics and biomedical data at scale using containerized workflows.

We are an advocate for physicians and patients, supporting them with unsurpassed integrity, regulatory compliance, and clinical expertise. Our pledge to deliver the highest professional operating standards in the laboratory service industry coupled with ongoing research and support exemplifies our commitment to being provider engaged and patient focused.

Hera Biotech is developing and commercializing a non-surgical test for endometriosis diagnosis and staging.

Hexagon Bio is a biopharmaceutical company pioneering the discovering novel payloads for antibody-drug conjugates (ADCs) to address critical unmet needs in oncology. Leveraging a proprietary platform, the company mines cytotoxic small molecules from microbial genomes for use as ADC payloads. Advances in DNA sequencing have enabled the identification of both existing ADC payloads—such as topoisomerase and tubulin inhibitors—and novel payload mechanisms targeting essential cancer pathways such as protein translation. Hexagon Bio is advancing a pipeline of next-generation ADC candidates with novel payloads designed to treat a wide range of solid tumors and hematological malignancies.

Honeycomb Biotechnologies is an early-stage company focused on making scalable solutions for storage and single cell genomic analysis of precious clinical samples. We enable translation of the rich biological information encoded in clinical specimens into high-resolution digital information, which can be queried and analyzed with sequencing. The resulting exponential growth in knowledge about the state of each person’s health and disease will enable the identification of new therapies and better targeting of current medicines in the era of precision medicine. Our first product is the “HIVE” – a single-use disposable device that is used (without any Honeycomb-specific instrumentation or equipment) for capturing, storing, and analyzing biological samples with single-cell resolution.

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage. For more information, please visit www.immuneering.com.

INanoBio’s mission is to develop high-accuracy early stage disease diagnostics using transformative nano-biotechnology platforms and machine learning. Extract systems scale information from complex disease biology, identify and detect disease specific molecular biomarkers, signatures at prodromal or pre-symptomatic stages. We believe most diseases can be detected early, enabling early personalized therapeutic intervention to preempt full development of diseases, ushering in preemptive medicine.

Indiana University is a Higher Education institution that provides academic programs and conducts research.

Inocras is a company for whole genome sequencing, providing a comprehensive view of a patient's entire genetic profile through WGS analysis and interpretation. Focusing on cancer and rare diseases, we aspire to fundamentally change how the world treats genetically driven diseases with an unsurpassed WGS databank and an integrated platform for generating, collecting, and analyzing genomic data.

Inscripta® is a life science technology company committed to creating a cleaner, healthier, and more sustainable world through biomanufacturing. A global leader in genome engineering, our innovations are designed to unlock the full potential of the bioeconomy. We are committed to the continued development of critical technologies that enable scientists to bolster and expand domestic biomanufacturing, and spur new, safe, and secure biotech innovations. Inscripta supports customers around the world from facilities in Pleasanton and Burlingame, California. To learn more, visit Inscripta.com and follow @InscriptaInc.

Intelliseq provides state of the art solutions for next generation sequencing. A team of passionate and skilled bioinformaticians, geneticists and molecular biologists approaches next generation DNA sequencing challenges with creativity and flexibility.

Intus Bio is using its proprietary high-resolution, high-throughput assay and analysis technology to identify bacteria and deliver answers about the microbiome, with unprecedented detail, accuracy and scale. The company is powering groundbreaking research, discovery and services with clients and partners across the global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continues to develop new and innovative partnerships, technologies, and applications.

iRepertoire was the first to develop and commercialize immune repertoire sequencing technology and products. iRepertoire uses immune repertoire sequencing technology to access the body’s immunological memory, or “logbook” of all past infection and disease. Sequencing the immune repertoire can yield insights into the nature of the body’s immune response to disease and infection. The future market for iRepertoire will be in clinical and research applications that require immune assessment such as drug treatment monitoring, identification of minimal residual disease (MRD), immune monitoring after stem cell transplantation, vaccine studies, and biomarker development.  iRepertoire provides primer kits and amplification to sequencing services to examine the TCR and BCR immune diversity in both humans and mice. iRepertoire also offers access to its proprietary repertoire analysis tools with the purchase of its regent systems.  iRepertoire’s reagent systems allow researchers to easily and inexpensively generate their own Next Generation Sequencing libraries in the convenience of their laboratory and analyze their data with the iRepertoire’s proprietary software pipeline at no additional cost.This year, iRepertoire has launched automated immune repertoire amplification and extraction on their sister company’s iC-processor (iCubate, Inc.). iRepertoire is proud to be a part of the non-profit initiative R10K, or Repertoire 10,000, with the HudsonAlpha Institute for Biotechnology, which aims to study the immune repertoire of 100 different diseases. The company has developed two key indices to describe the immune repertoire, i.e., the diversity index and the sharing index. These indices allow iRepertoire to identify disease specific signatures for diagnosis, prognosis, and treatment guidance.

Isabl integrates the whole genome and transcriptome to inform cancer care

Jumpcode Genomics is changing the way scientists see their samples with our proprietary CRISPRclean® technology. Combining CRISPR-based technology and next-generation sequencing (NGS) they can now search for and find novel signals they previously couldn't. Our technology removes unwanted sequences, allowing researchers worldwide to extract greater insights. By increasing sensitivity and allowing access to a range of sample types, we're broadening the understanding of human biology in fields from research to clinical applications including infectious disease and oncology.

Kailos Genetics provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions. The Kailos test is an easily accessible genetic test catered to your lifestyle.

KBioBox is a Bioinformatics company that specializes in fast precision Off Target Analysis and Gene Edit BioDesign for genetic data.

KromaTiD, Inc. provides products and services for mutation detection and disease diagnosis. KromaTiD’s patented dGH™ chromosome imaging platform enables detection of all types of chromosomal rearrangements including previously undetectable cryptic inversions.

Lab Genomics, LLC (LG) is focused on delivering individualized medical care through molecular and genetic diagnostics.

LC Sciences is a global biotechnology company providing products and services to genomics and proteomics researchers across an array of markets for nucleic acid/protein analysis, biomarker-discovery and drug development. Our innovative products and comprehensive services are based on several unique, core technology platforms developed by the scientists here at LC Sciences. A wide range of microarray service products are based on our µParaflo® microfluidic on-chip synthesis technology. This technology enables us to provide unique and customizable arrays of oligonucleotides, peptides, and their analog molecules. Our line of microarray services includes microRNA profiling, custom oligonucleotide (aptamer) screening, and peptide arrays for epitope mapping, protein kinase substrate profiling, and phosphopeptide binding assays. The OligoMix® technology has significantly reduced the cost and increased the speed of highly multiplexing genome-scale experiments such as exploration of small RNAs and designer gene/DNA library synthesis. OligoMix® technology has been applied to library construction of various biomolecules, sequence capture for targeted next-gen sequencing, and synthetic biology. The recently developed OligoFix™ strategy for error correction of microarray synthesized oligos has greatly improved the utility of OligoMix® for synthetic biology applications. The game-changing VariantPro™ multiplex-PCR based targeted sequencing system provides a simple, robust process delivering cost savings due to improved sequencing efficiency. Unlike singleplex methods with limited scalability and inflexible or traditional multiplex methods that suffer from primer induced variation in coverage requiring additional sequencing depth, VariantPro™ combines the specificity of a singleplex PCR reaction with the scalability of a multiplex reaction into a single step via relay-PCR, requiring less sequencing depth per sample.

Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.

Genomic Prediction provides advanced genomic tests which improve IVF health outcomes. Genomic Prediction Inc. (GP) was incorporated in Delaware, May 1, 2017. The research insights which led to the creation of GP stretch back much further. Research and data exchange agreements to develop molecular methodology, signed with some of the largest biotechnology vendors in the world, were ongoing as early as 2015. In the decade prior, the founders’ work in embryology, detection of chromosomal abnormality, computational genomics, algorithms, and polygenic architecture led to GP’s superior and innovative methodology for the genetic testing of human embryos. GP’s products incorporate fundamental improvements on existing methods. GP offers IVF parents a cost-effective means to evaluate genetic risk due to chromosomal abnormality (ploidy), single-gene mutations, and polygenic diseases. Accurate understanding of the genomic architecture of human disease requires larger training datasets, greater accuracy, and a more rigorous, empirical basis of computational modeling (machine learning) than implemented in the past with simpler technologies and simpler computational methods. GP represents the next step in embryo genetic testing, combining dense, genome-wide genotyping methods with sophisticated validation-focused modeling, suitable for the information age.

MacVector is a comprehensive Macintosh sequence analysis application that provides sequence editing, primer design, internet database searching, protein analysis, sequence confirmation, multiple sequence alignment, phylogenetic reconstruction, coding region analysis, agarose gel simulation and a variety of other functions.

The mission of the Medical College of Wisconsin is to be a national leader in the education and development of the next generation of physicians and scientists; to discover and translate new knowledge in the biomedical sciences; to provide cutting-edge, interdisciplinary and compassionate clinical care of the highest quality; to improve the health of the communities we serve. Founded in 1893 as the Wisconsin College of Physicians and Surgeons. Formerly associated with Marquette University.

MEDIC Life Sciences is a biotechnology company that specializes in resurrecting cancer drugs from failed clinical trials using proprietary technology to produce 2 million different tumor samples for testing.

MicroGenDX provides qPCR+NGS sequencing for the detection of infectious diseases. The American Medical Association (AMA) and Medicare have issued a billing code to MicroGenDX to provide this testing service, recognizing this technology as medically necessary. MicroGenDX is trusted by over 39,000 physicians worldwide and has helped over 900,000 patients with diagnostic testing for their chronic and life-threatening infections. MicroGenDX is a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvements Amendments (CLIA) licensed clinical laboratory. Tens of thousands of patients with chronic and often life-threatening infections have benefited from MicroGenDX's work. MicroGenDX's NGS technology offers several advantages over traditional culture-based methods for identifying microorganisms. It can detect a wider range of microorganisms, including those that are difficult to culture or grow in a laboratory. It also provides more accurate and comprehensive results, as it can detect multiple microorganisms in a single sample and identify them at the species or strain level. Additionally, NGS technology is faster than traditional methods, allowing for quicker diagnosis and treatment decisions.  MicroGenDX's testing services are used in a variety of settings, including hospitals, long-term care facilities, dental offices, and veterinary clinics. Their technology has been applied to a wide range of clinical conditions, including chronic wounds, orthopedic infections, respiratory infections, and urinary tract infections, among others.

Diagnostics We build innovative diagnostic and monitoring tools that empower people to make better decisions about their health. Drug Discovery We translate early-stage research into customized RNAi and CRISPR Cas9 animal and cell models to accelerate drug development. Therapeutics We identify and validate new drug targets, unleashing the commercial potential of RNAi to benefit people on a global scale. Established in 2010 to harness the power of RNAi and genetic engineering technologies developed by our founders in the labs of the world's leading experts at Cold Spring Harbor Laboratory, Howard Hughes Medical Institute, and Harvard Medical School, Mirimus creates innovative research and clinical technologies to address health issues on a global scale. Today, Mirimus markets multiple unique and high-value drug discovery and diagnostic products and services, and is advancing a pipeline of therapeutic candidates in partnership with leading biopharma companies to create novel high-impact health care solutions that benefits society on a global scale. Mirimus' ability to leverage its cutting-edge science and proprietary technology platforms to rapidly create new, affordable technology and products at scale is core to the way we work. We embrace diversity and creativity and have a proven track record of innovative problem solving—which led to our recognition as a $1M grand prize winner of the XPRIZE competition by developing a radically affordable, rapid, non-invasive methodology for mass COVID-19 testing—driving us to make better drugs and detect disease earlier. At Mirimus, our ingenuity, respect for our colleagues' ideas and creativity, executional agility, and a commitment to global health equity combine to create a unique culture of innovation that delivers measurable progress.

Mission Bio is a company of passionate people dedicated to solving complex biological problems with precision engineering, innovative biochemistry, and supported bioinformatics. In 2014, the company was spun out of Adam Abate’s lab for high-throughput biology at the University of California, San Francisco (UCSF). Mission Bio’s precision genomics platform is based on the pioneering droplet microfluidics work of Abate and his team. Our mission is to help researchers and clinicians unlock single-cell biology to enable the discovery, development, and delivery of precision medicine. Visit missionbio.com to learn more.

Modalis Therapeutics Corporation (Tokyo Mothers 4883) is developing precision genetic medicines through epigenetic gene modulation. Modalis is advancing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM technology which enables the locus specific modulation of gene expression or histone modification without the need for double- stranded DNA cleavage, gene editing or base editing. Modalis is headquartered in Tokyo with laboratories and R&D facilities in Cambridge,

Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company's patented Fully Enzymatic Synthesis (or FES™), based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. FES technology will enable the reading and writing of DNA for many industries, including industrial synthetic biology and precision medicine, as well as emerging applications of nanomachines and bio-based electronics. Molecular Assemblies is headquartered in San Diego. *Fully Enzymatic Synthesis and FES are the trademarks of Molecular Assemblies, Inc.

Develops the LoopCap,™ a 4-step NGS workflow that removes the need for conventional library prep and generates a targeted, sequencer-ready library of molecules representing genomic regions of interest in a highly redundant manner.

Electronic Genome Mapping Setting a new standard in structural variant analysis Nabsys, the pioneer of electronic genome mapping (EGM), uses solid-state nanodetectors to survey long DNA molecules to construct high-density maps with long-range information required to detect structural variants (SVs). Unlike other DNA mapping technologies that rely on the use of expensive optical imaging or fluorescent labels whose resolution is inherently limited by light diffraction, EGM identifies tags in close proximity therebye producing superior resolution. This high-density information makes it possible to identify both balanced and unbalanced SVs as small as 300 bp, in addition to larger chromosomal aberrations and genetic variation missed by next-generation sequencing. EGM involves simple, intuitive workflows eliminating the need for cytogenetics technical expertise, while delivering on the promise of easy-to-use, accurate, low-cost, whole-genome SV analysis. Visit the new Nabsys: https://nabsys.com/ Meet the OhmX™ Platform: Explore the genome in high-resolution. From sample prep through analysis, the OhmX end-to-end solution allows you to detect balanced and unbalanced events and a broad range of structural variants with precision. High Resolution Detection of SVs as small as 300 bp with >100 kb read lengths Low Cost Low instrument and consumable costs compared to other technologies Small Footprint Entire platform fits within 30"x17" saving valuable benchtop space Easy to Operate Easy sample prep, automated run monitoring & minimal hands-on time Accessible Analytics Web-based UI for data mining SVs via Human Chromosome Explorer™ powered by Hitachi High Tech

NantOmics employs a comprehensive, integrated panomic approach to detect molecular alterations in individual tumors and inform personalized treatment options for patients with cancer. Whole genome sequencing of a patient’s matched tumor sample and normal sample pinpoints tumor-specific alterations at the DNA level, RNA sequencing confirms and gives relevance to mutations in DNA, quantitative proteomics measures the levels of clinically important proteins, and integrative analysis identifies disrupted pathways that are specific to the patient’s tumor.

Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women's health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment.  Through a cfDNA technology platform approach, we've pioneered noninvasive testing in unlimited applications—each with their own potential to revolutionize care for patients. #TeamNatera includes clinicians, scientists, biostatisticians, researchers, and laboratory professionals from around the world. Our diverse teams blend a passion for patients with deep clinical, scientific, and technological roots. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Interested in joining us on our mission to change the management of disease worldwide? Visit https://www.natera.com/careers-at-natera to learn how you can become a part of our talented team. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. Please be advised that Natera will reach out to candidates with an @natera.com email domain ONLY. Email communications from all other domain names are not from Natera or its employees and are fraudulent. Natera does not request interviews via text messages and does not ask for personal information until a candidate has engaged with the company and has spoken to a recruiter and the hiring team. Natera takes cyber crimes seriously, and will collaborate with law enforcement authorities to prosecute any related cyber crimes. https://www.natera.com/privacy/

Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, Nautilus (Nasdaq: NAUT) set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

Nebula Genomics is a genomics company that offers genome understanding, disease cure assistance, and data ownership through blockchain technology.

Neogen®'s Solutions Can Be Found at Every Step of the Food Chain. Neogen provides a comprehensive range of solutions and services for the food processing, animal protein and agriculture industries, not only helping to protect the world's food supply, but also enabling our customers to produce more efficiently and effectively than they could before. We are also proud to serve the companion and performance animal industries, as well as the fields of life sciences and toxicology.

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

Newomics is a biotech company that sells and develops innovative and integrative platforms for LC-MS. In particular, the award-winning multinozzle M3 emitter, with the MnESI ion source, enhances the ionization efficiency to achieve unprecedented sensitivity, throughput, and robustness. Our proprietary technology is based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS), and offers unprecedented robustness, sensitivity, specificity, and throughput for analyzing molecules from minute amounts of biospecimens such as blood and urine. Our core technologies are built upon the multinozzle emitter array (MEA) technology, invented from the Lawrence Berkeley National Laboratory (Berkeley Lab), which has won the 2012 R&D 100 award.

NEXT Bio-Research, Services continues a 23 year history in providing comprehensive integrated project support to investigators in the biotech and pharmaceutical sectors. We also provide medical testing services to physicians using state-of-the-art platforms. NEXT Bio-Research Services was founded by three long standing colleagues who have worked together these past 23 years and collectively represent more than 100 years’ experience in life science technologies. NEXT Bio-Research Services is focused in (1) clinical testing using molecular and biochemical techniques; (2) molecular genetics of pharmacogenomics and cancer; (3) contract research in drug discovery and development with private sector customers; and (4) laboratory support of human clinical trials. We function as an extension of your own laboratory in helping you to bring their products from discovery to market. Our laboratories are certified under the Clinical Laboratory Improvement Amendments (CLIA) act and our contract research services are offered individually or can be integrated to support product development from discovery to market with full regulatory support under FDA GLP Guidelines 21 CFR 58.

NinthBio is a software company serving Biotech. Our flagship product is "Homology Path", an application that designs the oligos for DNA synthesis. The value is how few oligos are needed to build a a group of similar DNA sequences. Think of the DNA you would need to test for a protein engineering campaign, or to optimize the affinity of an antibody. All require similar but ultimately unique DNA. Our customers can improve their Design, Build, Test Learn Cycle by 15X all while decreasing their DNA spend 10 fold. Researchers are rethinking where and what they are willing to explore given the power of Homology Path, opening the door for rapid and higher value discovery. Want to see how this can help your initiatives; request a demo token to access the capabilities of Homology Path.

Nucleus is the all-in-one DNA health test. We combine whole-genome sequencing — which analyzes nearly all your DNA — with your unique lifestyle factors, delivering the most comprehensive look into your health and well-being that's ever been available. With deeper insights, Nucleus empowers you to live your healthiest life.

OncoTAb, Inc., a North Carolina based biotechnology company, was founded by Mayo Clinic alumna Dr. Pinku Mukherjee, with a mission to improve the quality of cancer care by addressing unmet cancer diagnostic and therapeutic needs. The company has just launched its first product: Agkura™ Personal Score – a simple, non-invasive blood test that aids breast cancer detection in women with dense breast tissue. Roughly half of the women in the US have dense breast tissue and mammograms miss 50% of the breast cancers in these women, resulting in late stage diagnosis and mortality. Agkura™ Personal Score measures the biomarker tumor-associated MUC1 (tMUC1) and shows a trend of increasing value from benign disease through breast cancer stages 1 to 4. Women can monitor their personal score in conjunction with annual mammograms. A score above the normal range or an increase greater than normal variation will trigger a recommendation for diagnostic imaging (ultrasound or MRI), resulting in earlier stage diagnosis of breast cancer. The company is also working on developing treatments for breast and pancreatic cancers.

OneOme, co-founded by Mayo Clinic, is working to help providers incorporate pharmacogenomics into patient care by offering the RightMed Test and associated tools. The RightMed Test may help providers optimize medication selection for their patients by analyzing and reporting on 27 genes. OneOme is privately held, based in Minneapolis, MN. For more information, visit www.oneome.com and follow us here for updates.

OnsiteGene Inc. is a biomedical technology company developing on-site genetic testing based on a new sample prep and qPCR process.

At PacBio, we’re devoted to empowering you. Pioneering the future through biology takes vision. You have to look beyond the status quo to what’s possible. We know your vision can reveal the full potential of the genome, advance human health and the health of our planet. And that is why your vision and pursuit are at the very center of what our company does — our product design, our customer support model, our partnerships, and even our identity. We create the world’s most advanced sequencing systems to provide you the most complete and accurate view of genomes, transcriptomes, and epigenomes. Our founders invented a new way to study the synthesis and regulation of DNA, RNA, and proteins. Driven by a desire to advance human health, we’re harnessing advances in biochemistry, optics, nanofabrication, and more. We are passionate about developing products that empower scientists to explore the full spectrum of genetic variation in any organism — from unraveling the mystery of rare diseases to improving the world’s food supply. With world-class service and support, we keep your research progressing so you can focus on finding answers. We encourage you to see the whole picture — and consider us the partner you trust to see it too.

Panorama Medicine is a VC-backed startup founded by a multidisciplinary team of world-renowned computational and experimental RNA biologists. Panorama has created PAN, a drug discovery platform that integrates genomics, big data, and computing to develop therapeutic interventions for RNA defects in disease. Research by Panorama and other companies has demonstrated that aberrant RNA splicing underlies a significant number of human diseases. Building industry leading algorithms and vast amount of public and proprietary datasets, Panorama has built the PAN platform to predict splicing events as well as design and screen modalities to address the underlying causes. We look forward to collaboration with the global drug development community to advance medicine and contribute to human knowledge of biology.

PaternityUSA.comprovides comprehensive DNA testing services for paternity, ancestry, and other genetic inquiries.

PathogenDx, Inc. (PDx) is a biotechnology company that develops testing kits, automation, and software to detect pathogens in plants, food, and the body. The company's patented multiplexed molecular testing technology, Dynamic Dimensional Detection (https://pathogendx.com/science/) or D3 Array™, can rapidly detect and identify up to 50 pathogens simultaneously, in a single well test, in less than a single shift providing triplicate data per target/analyte for confidence and certainty in results with a simple and easy process. Our technology is equipment agnostic, and our analytics is automated through our cloud-based software. Our mission is to provide testing technology and solutions for the clinical, food, and agricultural testing markets for Better and Health and safety.

Staffed by expertly trained geneticists, veterinarians, and technicians, the lab at Paw Print Genetics is equipped with the latest technology for the testing and analysis of canine genetic diseases. Once your tests are completed, you receive a clinical report with results, interpretations and recommendations, in addition to a Canine Genetic Health Certificate™. The staff also provide genetic counseling and consultations.

Phalanx Biotech Group provides genomics research products and services worldwide to academic, pharmaceutical and biotech communities. We developed the OneArray® line of high-quality and affordable microarrays for expression profiling of whole genomes, microRNA, and custom targets. Our service specialists offer comprehensive services including sample preparation, expression analysis, and qPCR validation. In 2017, Phalanx is pleased to announce that it has added Next Generation Sequencing Services (NGS) and corresponding NGS Bioinformatics to its service offerings.

Disrupting research enzyme/protein production, we are the first to introduce a Taq Polymerase free from background DNA contamination. We are now proud to introduce our new RNA extraction free EF1 SARS-CoV-2 Detection Kit, CE marked for in vitro diagnostics! Find out how we plan to have the gold standard of testing available with results in less time it takes to explain your job to grandma!

Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. They offer a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples as well as industry-leading genome and metagenome assembly and analysis software. Founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs, the company’s mission is to empower scientists with state-of-the-art genomic tools that will accelerate breakthrough discoveries. The company serves academic and commercial researchers in diverse fields and industries.

We are a bioinformatics-based precision medicine platform company translating patient-specific and population-based medical big data into novel pharmacological clinical treatment decision support products and services. We offer a proprietary technology, the PredictMed Platform, designed to help clinicians and health systems optimize precision in the selection of appropriate medications, drug combinations and dosages that improve each patient's health, while also reducing adverse reactions. Our PrecīsMed platform represents a significant step forward in accurately assessing a patient’s complete medication profile. Physicians can finally see the full spectrum of medications present in the patient, and identify appropriate dosing levels for therapeutic effectiveness. PrecīsMed can accurately assess prescribing trends, medication adherence and EHR coverage, as well as define medication concentrations in patients with comorbid disorders.

Phenomix Sciences is a precision medicine obesity biotechnology company on a mission to conquer obesity globally through the use of proprietary testing and personalized lifestyle guidance. The company offers the MyPhenome™ test, exclusively licensed from Mayo Clinic, which measures DNA and metabolites related to obesity to improve weight-loss effectiveness. Phenomix Sciences is committed to advancing the understanding of obesity treatment through precision medicine and believes in the power of knowledge and accurate diagnosis.

A specialty pathology practice and reference laboratory providing diagnostic and contract research services to pathology and oncology practices, hospitals, biopharmaceutical companies and research institutions in the U.S., Canada and around the world.PhenoPath’s test menu includes a broad array of state-of-the-art immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis.PhenoPath now offers EGFR mutation testing using cell-free DNA isolated from plasma. Please see the links below for more information:

Phylos is a cannabis genetics company focused on helping growers of all sizes to succeed commercially with seeds that produce the highest quality cannabis in the most cost-effective way. Phylos supports commercial-scale cultivation with the industry's first Production-Ready Seed™: premium, phenotypically stable, fully-feminized F1 hybrid seeds that deliver exceptional flower quality, potency, vigor, and yield. Phylos also leverages its proprietary technologies and its cultivation, extraction, and formulation expertise to provide partners with unparalleled THCV genetics and natural, safe and effective ingredients.

As the leader in Decision Medicine™, Pillar’s technology platform drives significantly more efficient and accessible NGS testing with industry-leading accuracy and sensitivity. Pillar’s extensive portfolio applies across the entire patient journey, from profiling to therapy selection and monitoring, generating actionable insights to get patients on the right therapy faster In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly. For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%.

PrecisionLife is the clinical-stage precision medicine company for complex chronic diseases. Creating better diagnostic tools and more personalized treatment options for patients with unmet medical needs. Our analytics and AI is unique in its understanding of causal disease biology. Identifying biomarkers to stratify patients by molecular mechanism of either their disease or drug response and link individuals to the drug targets, trials and treatments that will benefit them. With these insights we significantly increase the probability of success throughout the biopharma and healthcare value chain. Accelerating, informing and de-risking drug discovery and clinical development, building highly predictive diagnostics, and in launching more personalized and preventative medicines. To learn more, visit precisionlife.com.

Predictive Biologybrings together stem cell biology, high throughput screening and genetics to elucidate molecular mechanisms underlying compound response.

Premier Medical Group is Clarksville's hometown healthcare choice. We have always called Montgomery County home, and we're proud to be part of Clarksville's legacy and growth. Established in 1995, Premier Medical Group is the largest physician-owned and directed, multi-specialty group in the Clarksville-Montgomery County area. With more than 50 board-certified physicians and mid-level providers, we provide a wide range of healthcare services to families and businesses throughout the region. Premier Medical has five medical specialties: Family Medicine, Internal Medicine, OB/GYN, Occupational and Travel Medicine, and Pediatrics. In addition, we offer ancillary services including Clinical Research, Diagnostic Imaging, Medical Laboratory, Virtual Visits, and two Same-Day Clinics that are open seven days a week. We have a modern, centrally located campus with a workforce of 338 active employees, placing us among the area's largest employers. Premier is recognized by the National Committee for Quality Assurance as a Patient-Centered Medical Home for team-based care, quality, and safety. We have received the Better Business Bureau Torch Award for Ethics, annual recognition since 2003 by the Medical Group Management Association, and we hold gold status as deemed by the Montgomery County Green Certification Program for ongoing sustainability initiatives. We are grateful that each patient chooses us for their healthcare needs. Visit PremierMed.com or call 931-245-7000.

At Primex Clinical Laboratories, we're dedicated to enhancing health with precision and passion. Since 1996, our presence in clinical diagnostics has been unwavering, serving diverse clients across Central and Southern California, Nevada, and American Samoa. We're more than a testing facility, our laboratory is a center of innovation and reliability. We pride ourselves on delivering personalized customer service, and high-quality testing with quick and accurate results, contributing to our community's health and well-being. Understanding the vital role of diagnostics in healthcare, we aim to be your most trusted lab partner. Our focus extends beyond recognition; we strive to gain your trust through personalized service, precise testing, and innovative solutions. We dedicate ourselves daily to advancing healthcare with meticulous care and a personal touch, shaping a healthier future. Learn more at Primexlab.com.

PrognomiQ aims to generate proteomic information with high accuracy, scale and speed. This proteomic data will be complemented with genomic, metabolomic and other health information to deliver first-in-class test products that enable early disease detection and treatment. Powerful, Untapped Disease Insights Built on a Proteomics Foundation: Until now, there have been major technical and economic barriers to broad-scale proteomics analyses, leaving this rich resource of molecular information largely untapped for clinical purposes. These barriers have now been largely addressed through next generation tools that can elucidate complex proteomics at scale. Complementary Molecular Information: Genomic data has made clear contributions to researchers' abilities to understand and more precisely treat disease, but it is has shown limited impact on early-stage disease detection. Proteomics provides direct information on the biological state of a cell, including disease at its earliest state, but proteomics data has been technically difficult to generate – until now. By complementing the new sources of proteomics data with genomics and other data, such as metabolomics, we now have the tools to generate powerful multi-omics data that will be the key to unlock the detection and treatment of disease at its earliest stages, when these diseases are most likely to be cured. Unlocking Disease Detection and Treatment with Multi-omics Data: We designed our proprietary multi-omics platform around the most robust approaches to generating proteomic, genomic and metabolomics data at scale, including the use of the Proteograph technology platform from the life science tools company Seer (NASDAQ: SEER) whom PrognomiQ spun out of in 2020.

ProPhase Labs Inc. (Nasdaq: PRPH) ("ProPhase") is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We're revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach.

Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.

Psomagen, Inc., formerly Macrogen Corp, delivers genomic sequencing services to the clinical, academic, and consumer markets. Psomagen's labs are US-based and CLIA and CAP certified. Not only is the company accredited to perform the highest quality Sanger sequencing, Next-Generation Sequencing and Microarray Gene Analysis, it is also networked with Macrogen's worldwide headquarters, stretching its capabilities and capacity across a diverse set of labs around the world. Learn more at psomagen.com.

QBench is a cloud-based Laboratory Information Management System (LIMS) that enables labs to streamline their entire testing workflow, from sample receiving to automated results reporting. We're the modern, configurable, easy-to-use solution that allows our customers to get a LIMS up and running faster. QBench eliminates the need to have spreadsheets, shared network folders, and paper­-based tracking systems. Automate your entire lab with our developer-friendly API, Inventory Management, Customer Portal, Billing, and Quality Management System modules. Contact us by email at sales@qbench.com or phone at (888) 680-5834 to request a demo of our software!

Quantigen serves as both a contract research organization (CRO) and an active patient diagnostic laboratory. We employ a highly collaborative, cross-disciplinary approach when formulating the best strategy to meet each client's unique translational needs. Our scientists, drawn from across academia, big pharma, and clinical laboratories, work in tandem during project planning and execution to deliver cutting-edge solutions: ones that ease the transition from bench to bedside. Whether performing diagnostic protocol optimization, biomarker development and validation, medical-device design, or early-phase clinical trials support, Quantigen leverages the insights of a diversely trained team to design projects that help to ensure a successful lab-to-clinic transfer process. For further information, contact us at: contact@quantigen.com.

Quantum-Si is a biotechnology company that focuses on genomics and medical devices.

Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion. Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories. Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients. Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions. The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals. More information is available at www.questdiagnostics.com. Language Assistance / Non-Discrimination Notice Asistencia de Idiomas / Aviso de no Discriminación 語言協助 / 不歧視通知 www.QuestDiagnostics.com/home/nondiscrimination

Quintara Biosciences specializes in providing high quality DNA sequencing and genomic services for life science research communities around the world. With labs located in MA, CA, CO, CT, NJ, and DC, we are poised and ready to help scientists move their research forward.

Our Somatic Genomics platform unveils a new universe of genetic variation to create transformational medicines. Learn more at Quotient-Tx.com

Ravata Solutions is a fertility and reproduction company that specializes in hardware and diagnostics to transform the IVF laboratory with automated assisted reproductive technologies (AART) and enhance human disease model development for pre-clinical studies.

RealSeq Biosciences’ core expertise includes innovative proprietary technologies for bias-free small RNA/miRNA NGS library construction, targeted NGS tools, and cf-RNA analysis (liquid biopsy) that form the basis of the Company’s life science research programs and product development.

Real Time Genomics develops analytical solutions that reduce the cost and complexity of extracting knowledge from raw genomic data. We deliver validated, accurate results that are redefining personalized medicine. ___________________________________________________________________________________ At Real Time Genomics, we have a passion for genomics. Our core competence is a commitment to know, anticipate and deliver to the needs of leading biological researchers. The company has deep computational expertise in algorithms, coupled with extensive product development capabilities and a seasoned commercial team with over 100 years of success in bringing genomics' innovation to the life sciences industry. Today,we offer solutions for genomic analysis to practitioners of next generation sequencing (NGS) technologies. These solutions include complete analytical platforms for genomics and metagenomics. We can install these platforms to your compute environment or provide you access to them through cloud computing.

Resolution Bioscience, a part of Agilent, is pioneering next generation cancer diagnostics that enable physicians to tailor treatments for each patient using only a blood test — a liquid biopsy. Our proprietary molecular analytics platform interrogates cell-free DNA for actionable information that, until now, has only been accessible through invasive biopsy procedures. We have developed over 50 focused panels and are currently working on companion diagnostics to support therapeutic approvals. We are dedicated to improving cancer outcomes through a suite of clinical tests to guide selection of targeted therapies and monitor their effectiveness over time.

Rxight, developed by MD Labs, is a pharmacogenetic program that helps patients get the right medication at the right dose, the first time, based on their genetic profile. Importantly, Rxight also helps patients avoid medications that are ineffective or could cause dangerous side effects or adverse drug reactions. The MD Labs Rxight team was invited to the White House to present this novel Precision Medicine program to the Office of Science and Technology Policy. Go to our website to learn more. MD Labs was founded in 2011 with the goal to specialize in prescription monitoring toxicology and serve physicians across the United States. Our founders, Matthew Rutledge and Denis Grizelj started the company with the goal of creating a more provider-friendly testing service that prides itself on delivering prompt, accurate, reliable and easy to understand results.

RyboDyn, Inc. is targeting the dark proteome to make new immunotherapies. We are unlocking and validating previously undiscovered, disease-specific targets that will impact the treatment of cancer and autoimmune diseases by driving a new wave of targeted therapeutics. Our "targets-to-assets" therapeutics development program is supported by a scalable, in-house platform for lead discovery and optimization. We aim to deliver first-in-class assets that recognize these targets for treating solid tumors and diseases lacking effective treatment options.

S2 Genomics is developing integrated sample preparation systems processing tissues and liquid samples into genomic samples.S2 Genomics is also developing single cell spatial sequencing™technology that will capture the spatial location,i.e., 3-dimensional coordinates, of single cells in tissue for NGS readout.

Sage Science products are built on the idea that science is more robust and reliable when it is based on high-precision, automated, reproducible technology instead of manually intensive steps that introduce variability and error. We look at molecular biology workflows and identify high-value steps that can be significantly improved with accurate, automated solutions. Our products not only reduce hands-on time and boost throughput, but they also improve data quality and downstream results for life science and diagnostic labs. The Sage Science portfolio includes products to perform DNA or cDNA size selection: Pippin Prep for short-read NGS platforms and the BluePippin for short and long-read NGS platforms. The SageELF provides whole-sample fractionation of DNA for various applications. The SageHLS offers a new twist on DNA target enrichment. DNA is first extracted from cells directly on the platform. Then Cas9 endonuclease/guide RNA complexes are used to excise and collect large targets (entire genes or genomic regions, up to 500MB in length) from a genome. Large target enrichment, called CATCH (Cas9 assisted targeting of chromosomal segments) is used to elucidate difficult genomic structures such as pseudogenes, SVs, and repeat elements. Sage Science is privately funded. It is headquartered and manufactures at 500 Cummings Center in Beverly, MA, USA.

Salimetrics supports thousands of salivary researchers in more than 20 countries around the world. Our assays have been used in more saliva-related published papers than any other assay in the field. We believe Salimetrics is a unique company. We combine uncompromising scientific process with human passion to deliver what we hope are superior products and services for saliva testing and collection. We provide consultation, assistance with study design, advice for funding, and support for all things saliva testing-related, because we believe saliva testing can help researchers learn and discover things that will translate to cures, treatments and understanding around the world. If you have a ground-breaking study, ideas for innovative saliva testing products, or simply need advice, please don't hesitate to contact us. We work with a diverse network of saliva researchers around the world. This network extends the salivary research community by providing credible, data driven results that advance the scientific field of salivary research. Together, we can make a difference. To place an order, request a quote, or have your questions answered please visit our website. https://salimetrics.com/contact/ We are always ready to assist you!

We are biotech company located in the Boston area, with a mission to revolutionize non-invasive diagnostics. The systems we are developing allow monitoring cancer patients'​ progress, as well as looking very early into pregnancy to gain a complete genetic picture of the fetus, all with a simple blood test.

SciGene manufactures and sells instruments, equipment and reagents for chromosome and FISH slide processing in cytogenetics laboratories.

Scisco Genetics Inc, a Seattle-based spin-off from the Fred Hutchinson Cancer Research Center, is a leading provider of sequencing services and products for genotyping the immune system.

The Warrington College of Business is one of the nation’s premier business schools. As a part of a Research 1 institution, Warrington is dedicated to an extensive research agenda in addition to cultivating the young minds of our future leaders of industry. The College is comprised of the Heavener School of Business, the Fisher School of Accounting, and the Hough Graduate School of Business. Together, these three entities provide a full and enriching business education experience that not only prepares our students for business success, but enables them to thrive in the global economy. The University of Florida Warrington College of Business intends to educate, inform and provide updated information on Warrington's activities and news and to support and promote Warrington's objectives for these activities through its social media site. All Warrington comments are made by Warrington designees. This site is not a public forum. Social media users may share ideas through commentary that is consistent with and furthers the objectives of a Warrington post and the University of Florida Warrington College of Business reserves the right to remove any comments that do not fall within this purpose.

Revolutionizing the healthcare industry by providing an integrated AI platform that provides personalized health recommendations based on a combination of your DNA, labs, and environmental factors. SelfDecode is the only company in the world providing ancestry-adjusted Polygenic Risk Scoring directly to the consumer. Through our R&D division (OmicsEdge), we are making precision health affordable to all by empowering organizations to easily build precision health products using our bioinformatics infrastructure. Our core abilities include ancestry-adjusted Polygenic Risk Scoring, which we license to other organizations.

Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address. For more information, please visit the Senti Bio website at https://www.sentibio.com.

SeqLL is a biotechnology company that specializes in Quantitative RNA & Specialty DNA Sequencing, offering True Single Molecule Sequencing technology.

We are excited to continue to support women's health under the Labcorp name. Follow us @Labcorp

seqWell was created to revolutionize NGS library prep to unlock the full potential of today’s DNA sequencing instruments. Our plexWell™ platform is a transformative library prep technology that allows for simple, scalable multiplexing of 100s to 1000s of samples without time- and cost-consuming normalization. plexWell has wide-ranging impact on applications from synthetic biology, targeted sequencing and single-cell analysis to low and high depth sequencing of human, plant, animal and microbial genomes. In addition to plexWell, seqWell is also developing library prep methods for reagent-based approaches for long-molecule phasing and read linking. We invite you to learn more at https://seqwell.com

Signature Science's consultants serve government and commercial clients through a wide array of technical offerings. We combine scientific rigor with proven quality assurance processes to deliver solution-focused, well-executed projects and contracts. Our expertise enhances the credibility and defensibility of government programs that provide for our national and homeland security. The knowledge and experience of our consultants span a wide array of disciplines that match the technical needs of clients and the management requirements of our business. We have credentials in chemistry, biology, microbiology, biochemistry, forensic science, statistics, data science, quality assurance, engineering, physics, and management.

Singular Genomics is driving innovation at the forefront of multiomics. Dedicated to supporting the scientific community, we focus on creating scientific advancements influenced by real-world feedback and solution-oriented development. As a publicly-traded life science technology company, we specialize in advanced next-generation sequencing (NGS) and multiomic technologies, developing products that empower researchers and clinicians. The G4 Sequencing Platform, our first commercially available product, is an innovative benchtop sequencer featuring a novel 4-color rapid sequencing-by-synthesis (SBS) chemistry and advanced engineering, providing single-day turnaround times for various applications. Our recently launched G4X Spatial Sequencer, which is an upgrade to the G4 Sequencing Platform, is designed to offer high throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues. We are committed to unlocking the potential of our core technologies to reshape the future of multiomics. We offer a dynamic, fast-paced, results-oriented environment where employees can make a significant impact. Innovation, continuous learning, multi-disciplinary collaboration, and diversity of thought are pillars of our culture.

info@smlgenetree.com | www.smlgenetree.com | SML Genetree is recognized as a premier partner in developing technology and on-time delivery, providing both basic research of molecular biology and applied research in molecular diagnosis. SML Genetree is an affiliate of Samkwang Medical Laboratories (SML), one of the largest diagnostic commercial labs in South Korea in 1985.

SoftGenetics, LLC is a biotechnology company based out of 100 Oakwood Avenue Suite 350, State College, Pennsylvania, United States.

Sorenson Genomics specializes in DNA testing in forensic science, and research projects. Their expertise in human genomics includes DNA genotyping, DNA sequencing, and fragment analysis for use in population genetics and human genotyping.

Sunrise Medical Laboratories. We put people first. For over 40 years, we at Sunrise Medical Laboratories have consistently provided our member physicians and their patients with the most accurate and diagnostically meaningful results possible. Our success stems from our commitment to three essential principles. Courtesy Whether you're a physician or a patient, your needs are our top priority. We are committed to providing prompt service, timely notice of appointments and results, and empowering our employees with the answers to any questions you may have. Compassion We know that medical testing can sometimes be worrisome or stressful. For this reason, we train our staff to provide information, care and comfort whenever needed. Whether it's distracting a child during a blood draw or explaining a complex test, we're glad to go the extra mile for each and every patient. Professional Expertise We continually invest in the most advanced technologies so that we can provide the highest quality medical laboratory services available. We are fully licensed and accredited by The College of American Pathologists (CAP), New York State Department of Health, the Center for Medicare and Medicaid Services (CLIA), U.S. Department of Health and Human Services (Medicare), and the Pennsylvania Department of Health. Because your well-being, comfort and peace-of-mind are utmost to our success, we are proud to say, "We take it personally".

Synbio Technologies aims to become the most trusted provider of DNA solutions that empower scientific discoveries by providing highly-accurate and cost-effective synthetic biology services and products for researchers around the world. We have developed a full range of DNA reading (sequencing), DNA writing (synthesis), and DNA editing (engineering) capabilities for various applications, including diagnostic DNA probes, precision medicine, protein production, antibody discovery, vaccine development, novel enzymes, molecular breeding, biofuel implication, and more. Our scientific capabilities cover all facets of DNA synthesis and engineering, offering a full range of support for molecular biology work, including but not limited to, oligo synthesis, gene synthesis, subcloning & PCR cloning, plasmid preparation, mutagenesis, DNA variant libraries, CRISPR sgRNA, protein expression and purification in multiple systems. Relying on our strong DNA sequencing, synthesis, engineering technology platform, and expertise in bioinformatics analysis, we have developed proprietary algorithms to facilitate and expedite the antibody discovery process. Our antibody discovery services include hybridoma sequencing, immune repertoire sequencing, antibody design and production, AI-guided heavy chain and light chain pairing, antibody humanization, affinity maturation, and sdAb.

Sysmex Inostics is a medical diagnostics company that specializes in cancer testing through liquid biopsy technology, catering to precision medicine.

The Tabula Rasa HealthCare family of companies provide new beginnings for our clients, through innovative service models and fresh approaches to healthcare technology. Our leaders understand that to maximize patient experiences and outcomes, they must help providers to balance efficiency and scalability with safety and individualization of care.

Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a Takara Bio company, develops, manufactures, and distributes a wide range of life science reagents under the Takara®, Cellartis®, and Clontech® brands. Our products support applications including stem cell research; NGS; gene discovery, regulation, and function studies; protein expression and purification; RNAi and gene editing; and plant and food research.

Terra Bioforge (formerly Varigen Biosciences) is developing new technologies for capturing and expressing natural product pathways. Learn about our DNAtrap™ custom cloning service which delivers verified clones of your DNA target (up to 100 kb) in just 10 days at http://www.terrabioforge.com. Learn about how our BigDNA™ metagenomics libraries can revolutionize natural product discovery at http://varigenbiosciences.com/products/.

Tesis Biosciences’ unique integrated medical platform is revolutionizing targeted genetic sequencing. Precision-based medicine to help treat major chronic diseases. Our mission is to change medicine by providing physicians, hospitals, and researchers with the tools to help patients treat and overcome major chronic conditions such as heart and lung disease, cancer, diabetes, and Alzheimer’s through advanced genetic testing. Through our collaborative efforts utilizing our unique processes, we help medical device and pharmaceutical companies bring to market products that improve the quality of life for patients.

Tessera Therapeutics is pioneering Gene Writing™—a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source.

TrimGen is a precision medicine company that specializes in pharmacogenomics for behavioral health and chronic pain.

TruDiagnostic is a state of the art epigenetic testing company, specializing in Biological Aging, Nutritional Deficiencies, and Cellular Systems Health based on DNA Methylation. We offer testing for clinical practitioners and their patients, and consumers. TruDiagnostic is dedicated to utilizing validated research and rigorous scientific standards to expand our knowledge and analysis into Epigenetics and Aging. We also participate in research studies, using our validated Biological Age test (TruAge) to verify claims from interventional products. Our goal for the future is to continue to develop our DNA Methylation analytical ability until we can successfully identify markers that can be used by physicians to diagnose age-related diseases before they show outward symptoms, and let them begin early interventions.

Truveta is a growing collective of health systems in the US with a mission of Saving Lives with Data. Truveta delivers the most complete, clean, and timely regulatory-grade EHR data for scientifically rigorous research. Truveta is trusted by leading life science, government, health system, academic and research organizations to accelerate adoption of new therapies, improve clinical trials, and enhance patient care.

Twist Bioscience is a synthetic biology company based in South San Francisco, California. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA. Twist Bioscience serves Life Science researchers who are changing the world for the better. Coming from diverse fields of medicine, agriculture, industrial chemicals and data storage, scientists use our synthetic genes, oligo pools, and NGS target enrichment to better lives and improve the sustainability of the planet. Twist Bioscience is uniquely positioned to help accelerate these efforts by providing precision at a scale that is otherwise unavailable. Our technology overcomes inefficiencies and enables cost-effective, rapid, precise, high-throughput DNA synthesis and sequencing. We offer both the quality and quantity researchers need now to rapidly realize opportunities ahead. Twitter @TwistBioscience Facebook facebook.com/TwistBioscience YouTube youtube.com/TwistBioscience #WeMakeDNA

Universal Sequencing Technology focuses on innovative Long-Read DNA Sequencing solutions. Our Tell-Seq technology simply turns a 2nd generation DNA sequencer into a 3rd gen, Long-Read Sequencer. The affordable TELL-Seq WGS library prep kit is used in Metagenomics, de novo Assembly, Whole Genome Phasing, and Structural Variant identification. We provide the kit and the analysis pipeline and all you need are the samples and some common lab equipment. No need to buy expensive 3rd generation sequencers. No need to buy droplet making equipment. No need to follow overly complicated protocols. No longer limited by genome size. The Tell-Seq WGS Library Prep kit is affordable without the added expense of an instrument. The protocol takes only 3 hours to run and can be used for genomes ranging from 1 Mb to 5 Gb. Again, this is Long-Read Sequencing Made Simple.

Valted Seq is a discovery stage biopharmaceutical company spearheaded by world-renowned scientists Dr. Ted Dawson and Dr. Valina Dawson of Johns Hopkins University. The company was founded on the belief that a deeper understanding of neurodegenerative pathways is essential to develop precision therapeutics and identify novel biomarkers for some of the most challenging neurodegenerative diseases, including Alzheimer’s and Parkinson’s. Valted Seq is part of the D&D Pharmatech/Neuraly family of companies, which works hand in hand with leading medical research institutions to advance groundbreaking healthcare innovations. ValtedSeq is focused on the advancement of NextGen sequencing at the single cell level, as well as developing assays for diagnostic biomarkers,

Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.

Variant Bio is developing therapies that will improve global health by studying the genes of people who are outliers for medically relevant traits. They’re using cutting-edge sequencing technology, statistical genetics, and machine learning to identify entirely new therapeutic targets.

Varigen Biosciences Corporation is using metagenomics tools to investigatemicrobial diversity and develop natural products.

At Veritas, we apply science and our global resources to bring genetic and genomic diagnostics to people to extend and significantly improve their lives. Our global portfolio includes preventive medicine, perinatal medicine, and genomic diagnostic services. In March 2022 Veritas announced that it was becoming part of LetsGetChecked, a global healthcare solutions company based in Dublin and New York. In keeping with our responsibility as a leading biotechnology company, we collaborate with healthcare providers, governments, and local communities to support and expand access to genetic and genomic medicine reliably and affordably around the world.

By informing veterinarians and pet parents about which mutations are causing their pet's cancer to grow and spread, we intend to open up the use of precision medicine to combat canine cancer in new and more effective ways. Vidium is dedicated to unravelling the genetic components of common and complex diseases, including cancer. As a result, the practice of medicine targeting these conditions can be more rational, more precise and more personal. Our focus is on shifting paradigms in cancer treatment to enable cures for cancer and other serious diseases in pets through programs at the intersection of personalized medicine and comparative genomics.

Vivid Genomics enables pharma companies to select and stratify the right patients for their clinical trials, increasing the probability of trial success and getting to an approved drug. We use machine learning and genomics to develop blood-based, genetic tests (“Genomic BiopsyTM”) for neurodegenerative diseases, beginning with Alzheimer’s.

Volta Labs is a genomics applications company that has developed a cutting-edge digital fluidics platform to maximize performance and scalability of sample preparation in genomics while providing unparalleled consistency. Volta is transforming the way biological research and analyses are performed, allowing scientists to focus on what they do best -- pushing the boundaries of biology. As a collective of scientists and builders working at the intersection of engineering and biology, we imagine a world where extracting vital information from biological samples is as simple as pressing a button. That's our vision, and we're turning it into reality. Our HQ is in Boston’s Seaport, where we develop and manufacture our technology. We believe in cross-functional collaboration and continuous learning – whether your interest is in biology, MechEng, CompEng, or simply joining a fast-growing startup striving to make the world a better place, we'd love to welcome you to our team. Check out some of our blog posts to learn more about work life at Volta.

Know your pet's whole story with the world's leading pet DNA test. As the most accurate pet DNA test on the market, Wisdom Panel™ helps you understand your pet on a deeper level with insights into breed mix, relatives, genetic health, and physical traits. With over 20+ years of experience in genetic testing and chosen by 4+ million pet parents, Wisdom Panel delivers insights so you can give your pet the best care. Every single test contributes to the largest veterinary genetic research study to help improve the lives of all pets.